Clinical Trial Update: A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase® [Phase 1, Phase 2]

View source ↗

Summary

A safety and dose-ranging study assessing intrathecal idursulfase via an intrathecal delivery device in pediatric Hunter syndrome patients with CNS involvement …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hunter Syndrome

Drugs mentioned

• Elaprase (idursulfase)
• Idursulfase (intrathecal administration) (idursulfase)

Snippet

Sponsor: Shire | Conditions: Hunter Syndrome | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-05-16